EMEA proposes measures to better manage Tysabri’s PML risks; positive opinions from CHMP include two on GSK products

22-01-2010 Comments (0)

AlemtuzumabArzerraBiogen IdecBiotechnologyCampathFludaraFludarabineGlaxoSmithKlineGSKNatalizumabNeurologicalOfatumumab InjectionOncologyOseltamivir PhosphatePharmaceuticalRegulationTamifluTysabriVaccines

The European Medicines Agency (EMEA) has finalized a review of Tysabri (natalizumab) and the risk of…

In order to access this content you need to be logged into the site and have an active subscription or trial subscription.  Please login, take a free trial or subscribe in order to continue reading.

A trial subscription will give you access to the latest news on The Pharma Letter for 7 days, in order to evaluate the paid service.   

Take a Free Trial

What you get

Access The Pharma Letter's latest news free for 7 days


PLUS... you can receive the Pharma Letter headlines and news roundup email free forever

Become a Subscriber

What you get

Unlimited access to The Pharma Letter site for a whole year
Only £70 per month or £720 per year


  • No-limits access to our the site with up-to-the minute news
  • Personalised news and email alerts
  • Online discussion forums and Q&A section
  • RSS news feeds that you can add to your favourite reader, or website
  • Daily news email alert, with the breaking news stories and news roundup

“Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. Its part of the key information for keeping me informed”

Nigel Brooksby, Chairman, Sanofi aventis UK Ltd

Back to top